Helle Krogh Ottow

Title: Helle Krogh Ottow: Innovator in TNF Antagonists

Introduction

Helle Krogh Ottow is a notable inventor based in Mårslet, Denmark. She has made significant contributions to the field of biotechnology, particularly in the development of TNF antagonists. Her work focuses on creating polypeptides that have improved binding characteristics and efficacy for therapeutic applications.

Latest Patents

Helle Krogh Ottow holds a patent for "TNF antagonists - TNF binding polypeptides based on human tetranectin C-type lectin like domains (CTLD) with improved binding characteristics and improved efficacy." This innovative patent includes polypeptides that comprise a TNF binding domain with the amino acid sequence KRWS-RYF (SEQ ID NO:1). The methods of preparing these polypeptides are also detailed in her patent. These polypeptides can be utilized in pharmaceutical compositions and for treating conditions mediated by TNF, such as rheumatoid arthritis.

Career Highlights

Helle is associated with Anaphore, Inc., where she continues to advance her research and development efforts. Her work has the potential to impact the treatment of various pathologies, showcasing her dedication to improving patient outcomes through innovative solutions.

Collaborations

Helle collaborates with talented individuals in her field, including Mette Munch and Thor Las Holtet. These partnerships enhance her research capabilities and contribute to the success of her projects.

Conclusion

Helle Krogh Ottow is a pioneering inventor whose work on TNF antagonists represents a significant advancement in biotechnology. Her contributions are poised to make a meaningful difference in the treatment of diseases like rheumatoid arthritis.